NCT04787289View on ClinicalTrials.gov

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

244

Participants

Timeline

Start Date

September 10, 2021

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
Ovarian CancerPlatinum-resistant Ovarian Cancer
Interventions
DRUG

Bevacizumab

Low standard dose of bevacizumab, combined with single agent chemotherapy (7.5mg/kg IV Q3w or 5mg/kg IV Q2w)

Trial Locations (2)

V2S 0C2

RECRUITING

Abbotsford Centre, BC Cancer Agency, Abbotsford

V5Z4E6

RECRUITING

BC Cancer - Vancouver, Vancouver

All Listed Sponsors
lead

British Columbia Cancer Agency

OTHER